Making economic evaluations more assessable to health care decision-makers Editorial Pages: 246 - 247
Economic burden of obesity and its complications in Germany Beate SanderRito Bergemann Original Papers Pages: 248 - 253
Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden Jonas LundkvistDavid BergqvistBengt Jönsson Original Papers Pages: 254 - 262
Should one use smokeless tobacco in smoking cessation programs? Mikael BaskMaria Melkersson Original Papers 26 August 2003 Pages: 263 - 270
A Markov model of treatment of newly diagnosed epilepsy in the UK E. RemákJ. HuttonI. Adriaenssen Original Papers 24 May 2003 Pages: 271 - 278
Financial incentives and the supply of laboratory tests Fredrik CarlsenJostein GryttenIrene Skau Original papers Pages: 279 - 285
Health care reform in six Central European countries Mark J. C. NuijtenAgota SzendeMonika Laskowska Original Papers 27 June 2003 Pages: 286 - 291
An exponential representation of health state utility Michael HappichAxel Muehlbacher Original Papers Pages: 292 - 294
Testing assumptions of quality-adjusted life-year calculations Ariel Béresniak Commentary 21 June 2003 Pages: 295 - 295
Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines Ewa OrlewskaPiotr Mierzejewski Original Papers Pages: 296 - 303
Modeling risk-adjusted capitation rates for Umbria, Italy Elaine J. YuenDaniel Z. LouisJoseph S. Gonnella Original Papers Pages: 304 - 312
The lag between effectiveness and cost-effectiveness evidence of new drugs Boyka StoykovaMichael DrummondJos Kleijnen Original papers Pages: 313 - 318
An overview of the Greek pharmaceutical market V. KontozamanisE. MantzouneasC. Stoforos Pricing and Reimbursement Pages: 327 - 333
